Over the past year, there has been an increased spotlight on domestic manufacturing operations. This is largely due to a direct push by the current administration.

What state did Olympia get approval in?

Olympia Pharmaceuticals, a 503A and 503B pharmaceutical outsourcing facility company, recently announced approval to expand into Mississippi. This means that the company is now licensed in 49 states.

While the move will provide patients in Mississippi with improved access to compounded pharmaceuticals, it will also increase the state’s manufacturing capabilities in general.

Olympia CEO Mark Mikhael spoke with Pharmaceutical Executive about the expansion and how its impacting the company’s ongoing strategy.

Pharmaceutical Executive: What is Olympia's expansion strategy?
Mark Mikhael: Our goal is to provide our medications to patients nationwide. Securing state licensure involves rigorous qualifications, extensive documentation, and thorough inspections – it’s no small undertaking. We are proud of our quality, regulatory, engineering, and production teams for consistently prioritizing compliance in everything they do. Without their commitment and expertise, we would not have the national footprint we do today.

PE: Can you discuss the impact of receiving licensing approval in Mississippi?
Mikhael: With licensure in Mississippi, we are now able to distribute medications directly to clinics for office use and fulfill patient prescriptions throughout the state. This milestone not only expands access to our products for local healthcare providers but also strengthens our ability to support clients with nationwide operations. Many of our clients are multi-state or national chains, and obtaining licensure in Mississippi allows them to rely on Olympia as their primary provider for medications, ensuring consistent quality, compliance, and timely delivery across their entire network. This achievement reflects our ongoing commitment to broadening access while maintaining the highest standards of service and safety.

PE: How does going from a multi-state operation to a (nearly) national operation impact your strategy?
Mikhael: We're proud to have had a presence in the national market for some time now already. Even so, the foundation of our strategy is set in our dedication to regulatory compliance and quality assurance. Making certain we've crossed our T's and dotted our I's, not just for state and national inspections, but for our operations year-round, is paramount to our continued success. Whether we serve four states or 49, our commitment to excellence remains the same.

PE: How would you describe the national pharmaceutical market?
Mikhael: Nationally, we're seeing the pharmaceutical market driven more and more by access, affordability, and patient agency. Over time, especially with the heightened focus on longevity, weight management, and overall wellness, we've also seen a rise in patients wanting to put their healthcare back into their own hands. It's given us a great opportunity to advocate for alternative therapies in pursuit of better patient outcomes, and we anticipate this continuing to drive the national market as time goes on.